Last reviewed · How we verify

Antithyroid Drug — Competitive Intelligence Brief

Antithyroid Drug (Antithyroid Drug) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antithyroid agent. Area: Endocrinology.

phase 3 Antithyroid agent Thyroid peroxidase (TPO) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Antithyroid Drug (Antithyroid Drug) — Seoul St. Mary's Hospital. Antithyroid drugs inhibit thyroid peroxidase and reduce thyroid hormone synthesis to treat hyperthyroidism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Antithyroid Drug TARGET Antithyroid Drug Seoul St. Mary's Hospital phase 3 Antithyroid agent Thyroid peroxidase (TPO)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antithyroid agent class)

  1. Seoul St. Mary's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antithyroid Drug — Competitive Intelligence Brief. https://druglandscape.com/ci/antithyroid-drug. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing